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The 2019 Human Genome Meeting (HGM2019) of the
Human Genome Organization (HUGO) was held in
Seoul, Korea, from 24 to 26 April 2019, at Ewha
Woman’s University on their beautiful campus (https://
en.wikipedia.org/wiki/Ewha_Womans_University). The
twenty-third HGM was a truly international event,
attracting some 507 registrants from 29 countries span-
ning 6 continents who interacted both formally and in-
formally at 4 plenary lectures, 10 parallel scientific
sessions, 10 ancillary events, such as workshops, lunch-
eon sessions, 2 social events, poster sessions, and inter-
actions with exhibitors. (https://www.hugo-hgm.org/
program/scientific). Furthermore, the HGM in Seoul fea-
tured 42 international and 7 local distinguished speakers
highlighting the worldwide draw of this annual meeting.
Selected highlights from the plenary sessions
Diana Bianchi (National Institutes of Health, NIH, USA)
presented in her lecture entitled “Prenatal Genomic
Medicine: Transforming Obstetrical Practice and New
Biological insights” her view on the biggest example of
the impact of genomics in clinical medicine. The presen-
tation was based on the description of the changes in
obstetric practice as a result of the application of non-
invasive prenatal testing (NIPT). The reduction of inva-
sive diagnostic procedures is an important and relevant
goal since miscarriages as a consequence of older pro-
cedures would be eliminated. It is important though that
any false-positive results (a very low percentage, indeed)
may be a probable finding, to be verified with other
methodologies before arriving at a final conclusion and
making clinical decisions.
Harry Ostrer (Albert Einstein College of Medicine,
USA) presented his personal journey through human
genetics and genomics as a physician and researcher
over some 30+ years. Harry’s talk entitled “Personalized
Medicine, Precision Medicine and Global Health”
highlighted the scientific and life insights he gathered
over the decades which include his ethnic group’s ge-
netic history and 103+ prevalent mutations that could
serve as group-specific preventive genetics in (Ashken-
azi) Jews. He highlighted the importance of dissecting
genetic mechanisms and pathways using contemporary
technologies for understanding the pathogenesis of dis-
orders of sex development and other disorders. He
showed how lessons from rare diseases of DNA repair
could be applied for understanding pathways of common
cancer susceptibilities and that challenging oneself to
move beyond one’s comfort zone could lead to more
impactful research. Ostrer also discussed his role as a
sole plaintiff with standing in the landmark BRCA case
against Myriad Genetics in the USA, which reset the
framework for intellectual property in human genetics.
One of the highlights of the HGM in Seoul was the
presentation by Leslie Biesecker (NHGRI, the National
Human Genome Research Institute, USA, and current
President of the ASHG, the American Society of Human
Genetics; Fig. 1) entitled “The Myths of Clinical Genom-
ics.” Les persuasively argued for an urgent change of
paradigm in the use of genomics in medicine: moving
away from treating a patient’s disease to preventing it in
the first place. He also recommended balancing risks
and benefits in medical genomics. Finally, Biesecker pro-
posed a “positivist view” of genomics embracing widely
implemented genetic testing, secondary findings, carrier
screening, and pharmacogenetics. The talk led to a lively
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discussion with the audience including a comment by
one of us (JKVR) that genomics had already once before
precipitated a radical cultural change when we transi-
tioned from genetics into genomics. This change in-
cluded switching from hypothesis-driven research to
more discovery-based investigations, at the time often
termed “fishing expeditions.”
V. Narry Kim (Institute of Basic Sciences, South
Korea) presented her lecture entitled “RNA Terminal
Modification in Gene Regulation.” She described a novel
technology developed in her lab called TAIL-seq which
reveals the 3′-end sequences of RNA. Using TAIL-seq
she discovered that certain mRNAs have mixed poly(A)
tails, and deadenylation of these mRNAs is stalled in the
presence of G, U, or C bases. Furthermore, her recent
work has shown that TENT4A/B (which are terminal
nucleotidyltransferases) produce mixed tails which shield
mRNAs from rapid degradations. Narry’s work has re-
vealed a new factor in post-transcriptional regulation.
Kim also discussed the potential of using mixed tailing
as an RNA-based gene therapy which could enhance the
stability of mRNAs.
Noteworthy sessions from the parallel tracks
In the microbiomics session, Eran Segal (Weizmann Inst,
Israel) presented major strides in personalizing antidia-
betic diets, by calibrating the stabilizing vs. destabilizing
effects on blood glucose level of large numbers of nutri-
ents in a 1000-p Israeli cohort. The effects of the nutri-
ents and composite diets on the prediabetic state turns
out to correlate with lifestyle, metabolome, microbiome,
and clinical data. His group developed an algorithm
which reproducibly predicts the stabilizing vs destabiliz-
ing effects of different isocaloric diets in different people.
Strikingly, some meals that caused pronounced glucose
peaks in one person had only mild effects on others.
The resulting personalized prediabetes prevention ap-
proach is now being employed in Israel and the USA.
Second, also remarkable, the microbiome of persons
with different ancestry but the similar environment was
found to be largely similar, suggesting that gut micro-
biome composition is dominated by the environment ra-
ther than by genetics. Finally, specific microbial
subgenomic variations (SGV) were found, which associ-
ated with host risk factors both in the Israeli cohort and
in the Dutch Lifelines cohort. In the next talk, Cisca
Wijmenga (UMC Groningen, Netherlands) used the
same Lifelines cohort to take gut biology and epidemi-
ology another step further by creating 3D mini-guts-on-
a-chip from hiPSC cells from the Lifelines-DEEP cohort,
a section of Lifelines extensively typed by host and
microbiome sequencing, genetics, metabolomics, and
deep phenotyping. The chip-based system allows for
controlled modeling of internal and external intestinal
stimuli, including cultured microbes, that can be ana-
lyzed by imaging and cellular and molecular read-outs.
Such gut-on-a-chip systems have great potential to im-
prove our understanding of multifactorial diseases like
inflammatory bowel disease and celiac disease and may
help to accelerate the development of therapies. In the
last talk of this session, George Weinstock (Jackson Lab,
USA) showed the utility of well-designed inbred and
crossbred mouse strains to study the host genetic con-
trol of microbial communities.
In the cancer genomics session, Nick Papadopoulos
(Johns Hopkins, USA) presented the design and progress
of the CancerSEEK approach, using multi-omics based
on DNA variants in oncogenes and proteomics of a judi-
cious selection of oncoproteins to detect subclinical, un-
diagnosed cancers as well as determining the cancer
type. This approach, based on large datasets of UK Bio-
bank, is expected to greatly improve the success of the
early intervention. Currently, the work is in the valid-
ation stage using prospective samples from several co-
hort studies. In the next talk, Nic Waddell (Berghofer
Institute, Australia) gave an overview of the current sta-
tus and progress of NGS-based immunotherapy,
highlighting the search for individualized predictors of
the success or failure of the current modalities of cancer
immunotherapy.
The single-molecule session contained some outstand-
ing technological highlights of the meeting. In the first
talk, Long Cai (CalTech, USA) blew away the audience
by identifying, locating, and quantitating up to 10,000
Fig. 1 Les Biesecker giving his plenary presentation at HGM2019 in
Seoul, Korea, on the future of clinical genomics
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transcripts in formalin-fixed single cells and tissue sec-
tions in situ. He did this by reproducibly hybridizing and
washing, in up to 80 successive rounds, complex probe
libraries labeled with 3 fluorescent channels. This seq-
FISH+ system generates unique temporal bar codes for
all the RNAs in the sample, much like sequencing, thus
yielding the required detection complexity. Indeed, the
sequentiality is capable of resolving signals well beyond
the optical diffraction limit of the microscope and cell
size. Examples were shown of subcellular RNA
localization, resolution of processes in interacting cells,
and following the fate of nascent RNAs using intronic
probes. Due to the power of the technology, it is plaus-
ible that direct in situ sequencing may even substitute
the broadly used single RNA sequencing in large-scale
consortia projects. In the next talk, Efrat Shema (Weiz-
mann Institute, Israel) applied single-molecule imaging
of individual nucleosomes as a tool to decipher the his-
tone code at single nucleosome level, and combined this
with sequencing the attached DNA to derive the precise
genomic position of the epigenetic marking under study.
This high-density fluorescent probing approach estab-
lishes multi-layered comprehensive data of the epige-
nome and seems amenable to a plethora of thus far
intractable biological queries. In a third remarkable talk,
Roser Vento (Wellcome Sanger Institute, UK) analyzed
the female reproductive tissue using first-trimester pla-
centas with matched maternal blood and decidual cells
with the single-cell transcriptome. She analyzed HLA
and immunomodulation, elaborating transcriptional pat-
terns related to health and diseases, including pre-
eclampsia, which is related to HLA. To get broader bio-
logical insights on how reproductive tissues work, she
has constructed an interactome map of all the secreted
peptides versus all receptors that are expressed in all the
cells: such an approach is very useful to understand how
cells are likely to interact during early human pregnancy.
In the session on consanguinity/rare genetics and car-
rier screening Fowzan Alkuraya (King Faisal Specialist
Hospital and Research Centre, Saudi Arabia) presented
his extensive experience utilizing high throughput DNA
sequencing of recessive disorders in Saudi Arabia. The
application of this technology has allowed the
characterization of the genetic basis of different Mendel-
ian diseases not only in research settings but also in the
clinic. He elegantly demonstrated that as the data con-
tinue to accumulate, our understanding of genes, path-
ways, and molecular mechanisms will continue to evolve
and translate into better diagnosis, prognosis, and ther-
apies for these severe disorders prevailing in this coun-
try. Eva Maria Cutiongco-De La Paz (University of the
Philippines, Manila, Philippines) presented her interest-
ing data concerning “Identifying Genetic Variants Con-
ferring Susceptibility to Infection in the Indigenous
Population of the Philippines.” She demonstrated that
common and rare FUT2 and/or A2ML1 gene variants
confer susceptibility to otitis media, likely by modifying
the middle ear microbiome through regulation of A anti-
gen levels in epithelial cells. These studies suggested that
multiple combinations of common and rare genetic vari-
ants plus environmental factors influence the individual
otitis media phenotype as a complex trait.
An important workshop on recent aspects of Open
Science organized by the HUGO Committee on Ethics,
Law, and Society (CELS), the Human Variome Project
(HVP) and the Ewha Institute for Biomedical Law and
Ethics also took place. Many aspects were discussed.
Participants paid attention to the role of open education
and skills, Next Generation Sequencing metrics, the
changing business models for scientific publications, the
involvement of citizens science, and research integrity. It
is important to develop new models that bind together
“open science” and “open innovation,” experimenting
with new models of investment, to offer stakeholders op-
portunities to accelerate innovation in this context.
Some colleagues emphasized the right of citizens to
benefit from science and the potential harm to health
systems due to the non-use of data. At this point, the
need was suggested to increase science infrastructures
and the participation of citizens for more sustainable
health care systems (e.g., bioinformatics, biobanks, and
databases that are accessible by researchers, health care
specialists, citizens).
James Keck (The Jackson Laboratory, USA) was a
speaker in one of the two luncheon seminars of the last
day, with the title “Utilization of New Humanized
Mouse Models to Better Understand Emerging Immu-
nomodulation Therapies.” He delivered a very challen-
ging lecture on the utilization of the humanized mouse
model in the most recent impacts in oncology and ther-
apies based on immunomodulation. The characterization
of these models to be used in immune oncology was
depicted and the expectations, when more data will be
obtained, about the new humanized model for natural
killer cells are being obtained.
The Human Genome Meeting, for the second time
after the previous one in Yokohama, featured a special
session dedicated to trainees alone, in order to provide a
venue for students and postdocs to interact with each
other and established scientists invited for the events.
Fourteen excellent short talks were selected from the
submitted abstracts, which were presented between spe-
cials talks from seasoned scientists like Cisca Wijmenga,
Jonas Korlach, and David Bentley, who gave outstanding
advice to trainees. Advice ranged from risk-taking (take
the risk to explore new avenues!) to the importance to
develop original approaches and technologies, which will
always provide new types of data leading to new
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biological understanding. The best trainees were
awarded prizes (Fig. 2). The HGM also featured the
Chen Awards again. To provide a deep sense of the local
culture and cuisine, the meeting featured a wonderful
conference dinner featuring local entertainment.
Conclusions
The twenty-third Human Genome Meeting brought to-
gether over 500 participants from around the world to
discuss recent advances in human genomics. Scientific
highlights include placing genomics at the center of hu-
man wellbeing and disease prevention, advances in can-
cer and single-cell genomics, vibrant investigations of
the microbiome, acknowledgment of the contributions
of trainees, the future of scientific progress, and much
more. Finally, planned future HGMs include Perth,
Australia, next year, 2020, and Tel Aviv, Israel, in 2021
highlighting the worldwide nature of the HGMs.
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Fig. 2 Trainee awardees honored for their contributions at the HGM
in Seoul
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